Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
19.83
-0.21 (-1.05%)
Dec 20, 2024, 4:00 PM EST - Market closed
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 30.29, with a low estimate of 10 and a high estimate of 41. The average target predicts an increase of 52.75% from the current stock price of 19.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRIX stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 6 | 6 | 7 |
| Buy | 7 | 8 | 8 | 8 | 8 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 15 | 15 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $35 | Strong Buy | Maintains | $30 → $35 | +76.50% | Dec 11, 2024 |
| BTIG | BTIG | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +76.50% | Dec 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +46.24% | Dec 10, 2024 |
| BMO Capital | BMO Capital | Buy Initiates $35 | Buy | Initiates | $35 | +76.50% | Dec 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +46.24% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
55.76M
from 76.99M
Decreased by -27.57%
Revenue Next Year
59.06M
from 55.76M
Increased by 5.92%
EPS This Year
-2.84
from -2.65
EPS Next Year
-2.85
from -2.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 67.4M | 89.3M | 220.1M | |||
| Avg | 55.8M | 59.1M | 66.4M | |||
| Low | 40.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -12.5% | 60.1% | 272.6% | |||
| Avg | -27.6% | 5.9% | 12.4% | |||
| Low | -47.8% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.21 | -2.02 | -1.58 | |||
| Avg | -2.84 | -2.85 | -3.06 | |||
| Low | -2.98 | -3.28 | -3.95 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.